Replimune Group, Inc. (REPL)
8.03
+0.05
(+0.63%)
USD |
NASDAQ |
Feb 13, 14:13
Replimune Group Cash from Investing (Quarterly) : 75.12M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| CorMedix, Inc. | -291.32M |
| Verastem, Inc. | -8.279M |
| Sarepta Therapeutics, Inc. | 232.40M |
| Anavex Life Sciences Corp. | 0.00 |
| Ocugen, Inc. | -0.086M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -65.96M |
| Cash from Financing (Quarterly) | 10.45M |
| Free Cash Flow | -283.27M |
| Free Cash Flow Per Share (Quarterly) | -0.7169 |
| Free Cash Flow to Equity (Quarterly) | -66.11M |
| Free Cash Flow to Firm (Quarterly) | -64.13M |
| Free Cash Flow Yield | -40.01% |